September 26, 2024 09:00 PM EDT
Startups
Special

End­points 11 win­ner Iambic Ther­a­peu­tics: En­ter­ing the ‘show-me’ era for AI

Andrew Dunn

Senior Biopharma Correspondent

↑
  • CEO Tom Miller
  • To­tal raised $220 mil­lion
  • Head­quar­ters San Diego, CA

As two biotech rook­ies leav­ing long aca­d­e­m­ic ca­reers to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times